- Home
- CBUS vs IBIO Comparison
CBUS vs IBIO Comparison
Compare CBUS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBUS | IBIO |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 83.5M |
| IPO Year | 2017 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CBUS | IBIO |
|---|---|---|
| Price | $1.93 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $9.00 | $4.75 |
| AVG Volume (30 Days) | 458.8K | ★ 1.0M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.33 | 73.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,639,000.00 | N/A |
| Revenue This Year | $112.72 | N/A |
| Revenue Next Year | $83.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $0.56 |
| 52 Week High | $4.19 | $3.82 |
Technical Indicators
Market Signals| Indicator | CBUS | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 37.42 |
| Support Level | $1.51 | $1.36 |
| Resistance Level | $2.49 | $1.80 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 35.75 | 35.71 |
Price Performance
Historical ComparisonAbout CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.